Symbio Pharmaceuticals (4582 JP): Q3 FY12/24 flash update
Sales decreased by 57.1% YoY to JPY1.9bn, with operating, recurring, and net losses each at JPY2.8bn. SG&A expenses increased by 12.7% YoY to...
136 Views
Symbio Pharmaceuticals (4582 JP): 1H FY12/24 flash update
Sales decreased by 59.6% YoY to JPY1.3bn, with a gross profit of JPY996mn and a gross profit margin of 77.6%. Operating loss was JPY1.7bn,...
124 Views
SymBio Pharmaceuticals - Termination of coverage
Edison Investment Research is terminating coverage on Brooge Energy (BROG), Tyman (TYMN), SymBio Pharmaceuticals (4582), Aspire Global (0EAZ),...
15 Views
SymBio Pharmaceuticals - The first whole quarter of internal SymBio sales
SymBio reported Q121 sales of ¥1.42bn of its drug Treakisym (bendamustine) for hematologic malignancies. This is the first quarter in which the...
568 Views
SymBio Pharmaceuticals - Treakisym RTD approved
SymBio announced on 23 September 2020 that it has received approval from the PMDA for the ready-to-dilute (RTD) formulation of Treakisym...
213 Views